Newsletter Signup | Join Community
Erleada prolongs survival in non-metastatic Castration-resistant Prostate Cancer and for those with metastatic disease.
Initial results of KEYNOTE 365 study of Keytruda immunotherapy in prostate cancer released at 2019 ASCO
Xtandi® prostate cancer treatment Improves survival in metastatic and non-metastatic prostate cancer with rising PSA
Urologists are one of the experts that treat prostate cancer with surgery or prostatectomy. How do you choose one?
Oncotype DX - Prostate The Beginning of Individualized Treatment
Studies demonstrate that Zytiga improves outcomes in men with newly diagnosed and ADT resistant prostate cancer.
Darolutamide may represent new treatment option for men with rising PSA - evidence of ADT resistant prostate cancer.
UCLA Doctors Report that Five Days Sterotactic Radiation Therapy as Effective as 45 Days
Taxotere ineffective when used to treat early stage androgen sensitive prostate cancer.
Stay Current With Prostate Cancer Treatment Advances & Connect with Others
Harvard Study on Statins lowering risk of prostate cancer. …
Tell Your PSA Story: Has the PSA test helped in your prostate cancer journey? Its Prostate Cancer…